Skip to main content

Table 2 Difference in median OS and PFS between RCTs before and after 2012

From: Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation

 

DOX arm

Experimental arm

Before 2012

After 2012

p value

Before 2012

After 2012

p value

Median OS, month (95% CI)

9.4 (8.4–12.0)

14.5 (13.2–27.3)

0.008

10.8 (9.0–11.7)

16.3 (13.3–38.9)

0.028

Median PFS, month (95% CI)

5.1 (2.7–9.3)

5.5 (4.6–6.1)

0.951

4.0 (2.0–6.8)

6.3 (2.8–8.3)

0.135

  1. Abbreviations: CI, confidence interval; DOX, doxorubicin; OS, overall survival; PFS, progression-free survival; RCT, randomized controlled trial